These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
330 related articles for article (PubMed ID: 21980135)
21. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib. Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136 [TBL] [Abstract][Full Text] [Related]
22. Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle. Pretto F; Ghilardi C; Moschetta M; Bassi A; Rovida A; Scarlato V; Talamini L; Fiordaliso F; Bisighini C; Damia G; Bani MR; Piccirillo R; Giavazzi R Oncotarget; 2015 Feb; 6(5):3043-54. PubMed ID: 25460504 [TBL] [Abstract][Full Text] [Related]
23. MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model. Diaz-Montero CM; Mao FJ; Barnard J; Parker Y; Zamanian-Daryoush M; Pink JJ; Finke JH; Rini BI; Lindner DJ Br J Cancer; 2016 Oct; 115(8):920-928. PubMed ID: 27560553 [TBL] [Abstract][Full Text] [Related]
25. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration. Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888 [TBL] [Abstract][Full Text] [Related]
26. Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance. Zhitomirsky B; Assaraf YG Oncotarget; 2015 Jan; 6(2):1143-56. PubMed ID: 25544758 [TBL] [Abstract][Full Text] [Related]
27. Identifying resistance mechanisms against five tyrosine kinase inhibitors targeting the ERBB/RAS pathway in 45 cancer cell lines. Pénzváltó Z; Tegze B; Szász AM; Sztupinszki Z; Likó I; Szendrői A; Schäfer R; Győrffy B PLoS One; 2013; 8(3):e59503. PubMed ID: 23555683 [TBL] [Abstract][Full Text] [Related]
33. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells. Miyazaki A; Miyake H; Fujisawa M Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115 [TBL] [Abstract][Full Text] [Related]
34. Photoactivation of lysosomally sequestered sunitinib after angiostatic treatment causes vascular occlusion and enhances tumor growth inhibition. Nowak-Sliwinska P; Weiss A; van Beijnum JR; Wong TJ; Kilarski WW; Szewczyk G; Verheul HM; Sarna T; van den Bergh H; Griffioen AW Cell Death Dis; 2015 Feb; 6(2):e1641. PubMed ID: 25675301 [TBL] [Abstract][Full Text] [Related]
35. Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients. Jiménez-Valerio G; Martínez-Lozano M; Bassani N; Vidal A; Ochoa-de-Olza M; Suárez C; García-Del-Muro X; Carles J; Viñals F; Graupera M; Indraccolo S; Casanovas O Cell Rep; 2016 May; 15(6):1134-43. PubMed ID: 27134180 [TBL] [Abstract][Full Text] [Related]
36. Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines. Canter D; Kutikov A; Golovine K; Makhov P; Simhan J; Uzzo RG; Kolenko VM Can J Urol; 2011 Aug; 18(4):5819-25. PubMed ID: 21854714 [TBL] [Abstract][Full Text] [Related]
37. [Sunitinib induces autophagy via suppressing Akt/mTOR pathway in renal cell carcinoma]. Cao P; Jiang XJ; Xi ZJ Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 48(4):584-589. PubMed ID: 29263493 [TBL] [Abstract][Full Text] [Related]
38. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma. Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883 [TBL] [Abstract][Full Text] [Related]
39. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma. Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873 [TBL] [Abstract][Full Text] [Related]
40. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Ciamporcero E; Miles KM; Adelaiye R; Ramakrishnan S; Shen L; Ku S; Pizzimenti S; Sennino B; Barrera G; Pili R Mol Cancer Ther; 2015 Jan; 14(1):101-10. PubMed ID: 25381264 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]